BCR-ABL Inhibitor HS-10382

Preferred Label : BCR-ABL Inhibitor HS-10382;

NCIt synonyms : BCR-ABL Tyrosine Kinase Inhibitor HS-10382;

NCIt definition : An orally bioavailable, allosteric tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor HS-10382 targets and binds to the ABL myristoyl pocket, locking BCR-ABL into an inactive conformation, thereby inhibiting the activity of BCR-ABL and decreasing the proliferation of tumor cells. BCR-ABL fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells.;

Molecule name : TERN 701; HS-10382; HS 10382; TERN-701;

NCI Metathesaurus CUI : CL1792343;

Details

Origin ID

C187661;

UMLS CUI

C5706430;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Receptor Tyrosine Kinase Inhibition [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Inhibition of Cell Proliferation [NCIt concept]
- Signal Transduction Inhibition [NCIt concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- BCR/ABL1 Fusion Protein [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients